FDA 483 - Genentech, Inc. - August 11, 2023

An FDA inspection of Genentech, Inc. in South San Francisco, CA, identified one observation related to their role as a sponsor of a clinical study. The firm failed to notify the FDA about the termination, for cause, of a principal investigator's participation in an investigation. This indicates a lapse in regulatory reporting requirements for clinical trials.